PSIL Among Its Peers
End-of-day Nov 17, 2026 · 1 ETFs by 1M
| Returns | Today | 1W | 1M | 3M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| Total return | −2.9% | −11.7% | −12.5% | −32.8% | +2.7% | +10.0% | +53.1% | −78.9% | — | −79.4% |
| S&P 500 · VOO | −1.0% | −2.4% | −4.5% | −4.5% | +8.3% | +10.2% | +72.7% | +68.0% | +305.1% | — |
$118 of every $1,000 in PSIL is Definium
| # | Ticker | Company | Weight ▼ |
|---|---|---|---|
| 1 | DFTX | Definium Therapeutics | 11.78% |
| 2 | CMPS | Compass Pathways | 10.43% |
| 3 | HELP | Helus Pharma | 7.67% |
| 4 | LLY | ELI Lilly & | 6.79% |
| 5 | NBIX | Neurocrine Biosciences | 6.31% |
| 6 | RLMD | Relmada Therapeutics | 6.11% |
| 7 | ABBV | Abbvie | 6.06% |
| 8 | SPTX | Seaport Therapeutics | 5.33% |
| 9 | SUPN | Supernus | 5.25% |
| 10 | ANRO | Alto Neuroscience | 4.97% |
| # | ||||||
|---|---|---|---|---|---|---|
| 1 | DFTXDefinium Therapeutics | Healthcare | 11.78% | $1,178.16 | 153K | $4.6M |
| 2 | CMPSCompass Pathways | Healthcare | 10.43% | $1,043.06 | 494K | $4.1M |
| 3 | HELPHelus Pharma | Healthcare | 7.67% | $767.32 | 392K | $3.0M |
| 4 | LLYELI Lilly | Healthcare | 6.79% | $679.34 | 1,860 | $2.7M |
| 5 | NBIXNeurocrine Biosciences | Healthcare | 6.31% | $630.65 | 15K | $2.5M |
| 6 | RLMDRelmada Therapeutics | Healthcare | 6.11% | $610.76 | 663K | $2.4M |
| 7 | ABBVAbbvie | Healthcare | 6.06% | $606.48 | 8,071 | $2.4M |
| 8 | SPTXSeaport Therapeutics | Healthcare | 5.33% | $533.30 | 109K | $2.1M |
| 9 | SUPNSupernus | Healthcare | 5.25% | $524.70 | 71K | $2.1M |
| 10 | ANROAlto Neuroscience | Healthcare | 4.97% | $497.08 | 72K | $1.9M |
| 11 | JNJJohnson & Johnson | Healthcare | 4.93% | $493.18 | 6,842 | $1.9M |
| 12 | GHRSGH Research | Healthcare | 4.88% | $488.08 | 102K | $1.9M |
| 13 | NRXPNRX Pharmaceuticals | Healthcare | 4.06% | $406.33 | 741K | $1.6M |
| 14 | STIMNeuronetics | Healthcare | 3.50% | $350.35 | 1.1M | $1.4M |
| 15 | DRUGBright Minds Biosciences | Healthcare | 2.78% | $278.12 | 48K | $1.1M |
PSIL has no close peers in our data yet: […]
No peers with a full year of prices to rank against yet.
| Fund | Sharpe | Sortino | Volatility | Max DD | Beta | Fee / $10k |
|---|---|---|---|---|---|---|
| PSIL | −0.02 | −0.03 | 40.0% | −34.2% | 1.24 | $128 |
Estimated yearly cost excludes trading costs and assumes constant assets.
| Ex-date | Paid | Per share |
|---|---|---|
| Dec 22, 2025 | Dec 29, 2025 | $1.68 |
| Sep 22, 2025 | Sep 29, 2025 | $0.0201 |
| Jun 23, 2025 | Jun 27, 2025 | $0.0119 |
| Mar 21, 2025 | Mar 28, 2025 | $0.16 |
| Dec 23, 2024 | Dec 30, 2024 | $0.0548 |
| Sep 23, 2024 | Sep 30, 2024 | $0.11 |
| Sep 25, 2023 | Sep 29, 2023 | $0.34 |
| Sep 26, 2022 | Sep 30, 2022 | $5.41 |